HLP005
Serotonergic psychedelic
From Wikipedia, the free encyclopedia
HLP005, or HLP-005, also known as deuterated phenethylamine derivative and formerly as CYB005, is a serotonin receptor agonist and serotonergic psychedelic which is under development for use at non-hallucinogenic doses in the treatment of CNS disorders and neuroinflammation.[2][3][1]
| Clinical data | |
|---|---|
| Other names | HLP005; HLP-005; CYB005; CYB-005; Deuterated phenethylamine; Deuterated phenethylamine derivative |
| Drug class | Serotonin receptor agonist; Serotonergic psychedelic; Antiinflammatory drug[1] |
Interactions
Pharmacology
Pharmacodynamics
HLP005 acts as a serotonin receptor agonist and is a serotonergic psychedelic.[2][1] In addition, HLP005 may also inhibit serotonin and dopamine reuptake.[1]
Chemistry
HLP005 is a phenethylamine derivative and a deuterated compound.[2][3][1] The exact chemical structure of HLP005 does not yet seem to have been disclosed.[2][1] However, it appears to be closely related to CYB210010 (CYB2108; 2C-T-36 or 2C-T-TFM), which itself is non-deuterated.[6][7][8] In addition, HLP005's developer has patent protection for the compound, indicating that its chemical structure has been published in the patent literature.[2][6][4] Some notable phenethylamines patented by Helus Pharma include the non-deuterated CYB2108 (2C-T-36) and its deuterated form CYB2108D (fully deuterated methoxy groups at 2 and 5 positions).[4][5]
Research
HLP005 is under development by Helus Pharma (formerly Cybin).[2][3][1] As of November 2025, it is in the preclinical research stage of development for treatment of CNS disorders.[2][3] The drug was also under development for treatment-resistant psychiatric disorders, but development for this indication was discontinued in November 2025.[2] Other related drugs under development by Helus Pharma include the deuterated tryptamines HLP003 (CYB003) and HLP004 (CYB004).[1][9]